Friday April 19, 2024 | Last Update: April 19, 2024 EDT
GlaxoSmithKline plc (GSK) has announced in a press release that it will be acquiring Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and discovery stage HIV research assets. The HIV assets complement GSK’s global HIV business ViiV Healthcare’s existing portfolio.
Read more >>
Bristol-Myers Squibb Company has announced that it has granted an exclusive right to acquire Promedior, Inc., a clinical stage immunotherapy company pioneering the development of targeted therapeutics to treat fibrotic diseases, for about $1.25 billion, according to a press release issued by Bristol-Myers Squibb.
Just In
Most Read
1
2
3
4
5
